Form 8-K

8-K — Enveric Biosciences, Inc.

Accession: 0001493152-26-026364

Filed: 2026-05-29

Period: 2026-05-22

CIK: 0000890821

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Submission of Matters to a Vote of Security Holders

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-10.1 (ex10-1.htm)

EX-10.2 (ex10-2.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0000890821

2026-05-22

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

May

22, 2026

Date

of Report (Date of earliest event reported)

Enveric

Biosciences, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-38286

95-4484725

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(I.R.S.

Employer

Identification

No.)

Enveric

Biosciences, Inc.

245

First Street, Riverview II, 18th Floor

Cambridge,

MA, 02142

(Address

of principal executive offices) (Zip code)

Registrant’s

telephone number, including area code: (617) 444-8400

N/A

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

stock, par value $0.01 per share

ENVB

The

Nasdaq Stock Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of

Certain Officers.

May 22, 2026, the Compensation Committee recommended, and the Board of Directors (the “Board”) of Enveric Biosciences, Inc.

(the “Company”) approved and adopted, (i) a new form of Restricted Stock Unit Award Agreement (“RSU Agreement”)

and (ii) a new form of Restricted Stock Award Agreement (the “RSA Agreement”, and together with the RSU Agreement, the “Award

Agreements”), in each case under the Company’s 2020 Long-Term Incentive Plan, as amended (the “Plan”).

The

RSU Agreement provides for time-based vesting over a four-year period, with 25% of the award vesting on the first anniversary of the

grant date and the remaining portion vesting in substantially equal monthly installments thereafter, and generally provides that vested

units are settled upon a change in control or termination of service, subject to compliance with Section 409A of the Internal Revenue

Code. The RSU Agreement also includes provisions providing for full vesting upon a change in control, limited accelerated vesting upon

certain qualifying terminations, forfeiture of unvested units upon termination of service, and, in the case of a termination for cause,

forfeiture of vested but unsettled units.

The

RSA Agreement generally provides for time-based vesting on a specified vesting date, subject to continued service through such date,

with unvested shares forfeited upon a termination of service prior to vesting, and includes customary restrictions on transfer and provisions

regarding stockholder rights prior to vesting.

The

Award Agreements will be used in connection with future grants of restricted stock units and restricted stock to the Company’s

named executive officers and directors, as applicable.

The

foregoing description of the Award Agreements does not purport to be complete and is qualified in its entirety by reference to the full

text of the forms of RSU Agreement and RSA Agreement, copies of which are filed as Exhibits 10.1 and 10.2, respectively, to this Current

Report on Form 8-K and are incorporated herein by reference. The full text of the Plan is included in Exhibit 10.3.

Item

5.07 Submission of Matters to a Vote of Security Holders.

May 28, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). A total of 991,828 shares

of the Company’s common stock were present in person or represented by proxy at the 2026 Annual Meeting, which represented 52.54%

of the outstanding shares of common stock entitled to vote at the 2026 Annual Meeting and constituted a quorum for the transaction of

business. Holders of the Company’s common stock were entitled to one vote per share of common stock held as of the close of business

on March 30, 2026, the record date for the 2026 Annual Meeting. The matters submitted for a vote and the related results are set forth

below. At the 2026 Annual Meeting, each of the five matters were presented for a vote to the stockholders:

● The

election of six directors, to serve until the Company’s 2027 annual meeting of stockholders or until their successors are duly

elected and qualified (“Election of Directors”);

● An

advisory vote to approve the compensation of the Company’s named executive officers, as disclosed in the proxy statement (the “Say-on-Pay

Proposal”);

● The

extension of the approval of the Company’s Board to amend the Company’s Amended and Restated Certificate of Incorporation,

as amended (the “Charter”) to, at the discretion of the Board, effect a reverse stock split with respect to the Company’s

issued and outstanding common stock, including stock held by the Company as treasury shares, at a ratio of 1-for-5 to 1-for-15, with

the ratio within such range to be determined at the discretion of the Board (the “Reverse Stock Split Proposal”);

● The

extension of the approval of the Board to amend the Charter to, at the discretion of the Board, increase the authorized number of shares

of common stock from 100,000,000 to 5,000,000,000 shares (“Authorized Stock Increase Proposal”); and

● The

ratification of the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal

year ending December 31, 2026 (the “Auditor Ratification Proposal”).

The

proposal to approve the adjournment of the 2026 Annual Meeting was not presented for a vote.

The

final vote results for each of these five matters are set forth below.

1. The

votes cast on the Election of Directors were as follows:

Nominee

Votes

For

Withheld

Broker

Non-Votes

Michael

Webb

564,143

37,590

390,095

George

Kegler

531,522

70,211

390,095

Frank

Pasqualone

531,937

69,796

390,095

Marcus

Schabacker, M.D., Ph.D.

566,038

35,695

390,095

Joseph

Tucker, Ph.D.

565,386

36,347

390,095

Sheila

DeWitt, Ph.D

565,534

36,199

390,095

2. The

votes cast on the advisory vote for the Say-on-Pay Proposal were as follows:

Votes

For

Votes

Against

Abstentions

Broker

Non-Votes

569,552

26,884

5,297

390,095

3. The

votes cast on the Reverse Stock Split Proposal were as follows:

Votes

For

Votes

Against

Abstentions

793,344

190,175

8,309

4. The

votes cast on the Authorized Stock Increase Proposal were as follows:

Votes

For

Votes

Against

Abstentions

427,158

555,147

9,523

5. The

votes cast on the Auditor Ratification Proposal were as follows:

Votes

For

Votes

Against

Abstentions

960,728

19,347

11,753

For

more information about the foregoing proposals, please see the Company’s proxy statement for the 2026 Annual Meeting, together

with any supplements thereto. The results reported above are final voting results. No other matters were considered or voted upon at

the meeting.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

Number

Description

10.1

Form of RSU Agreement

10.2

Form of RSA Agreement

10.3

Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Registration Statement on Form S-8, filed with the Commission on March 24, 2025)

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date:

May 29, 2026

ENVERIC

BIOSCIENCES, INC.

By:

/s/

Joseph Tucker

Joseph

Tucker, Ph.D.

Chief

Executive Officer

EX-10.1

Filename: ex10-1.htm · Sequence: 2

Exhibit 10.1

WITH

EXECUTIVE EMPLOYMENT AGREEMENT FORM

RESTRICTED

STOCK UNIT AWARD AGREEMENT

ENVERIC

BIOSCIENCES, INC.

2020

LONG-TERM INCENTIVE PLAN

Award of Restricted Stock Units. Pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the “Plan”)

for Employees, Contractors, and Outside Directors of Enveric Biosciences, Inc., a Delaware corporation (the “Company”),

the Company grants to

(the

“Participant”)

Award under the Plan for _______________ (_______) Restricted Stock Units (the “Awarded Units”), with each

Awarded Unit representing the right, subject to the terms and conditions of the Plan and this Restricted Stock Unit Award Agreement (this

“Agreement”), to receive one share of Common Stock upon settlement of such Awarded Unit in accordance with

this Agreement. The “Date of Grant” of this Restricted Stock Unit Award is __________________. Each Awarded

Unit shall be a notional share of Common Stock, with the value of each Awarded Unit being equal to the Fair Market Value of a share of

Common Stock at any time.

Subject to Plan. This Agreement is subject to the terms and conditions of the Plan, and the terms of the Plan shall control to

the extent not otherwise inconsistent with the provisions of this Agreement. The capitalized terms used herein that are defined in the

Plan shall have the same meanings assigned to them in the Plan. This Agreement is subject to any rules promulgated pursuant to the Plan

by the Board or the Committee and communicated to the Participant in writing.

Vesting; Timing of Delivery of Shares. Awarded Units which have become vested pursuant to the terms of this Section 3 are

collectively referred to herein as “Vested RSUs.” All other Awarded Units are collectively referred to herein

as “Unvested RSUs.” For the avoidance of doubt, the vesting of Awarded Units pursuant to this Section 3(a)

shall not by itself result in the issuance of shares of Common Stock, and shares shall instead be issued only upon settlement in accordance

with Section 3(b).

Except as specifically provided in this Agreement and subject to certain restrictions and conditions set forth in the Plan, the Awarded

Units shall vest and become Vested RSUs as follows:

One-fourth (1/4th) of the total Awarded Units (rounded down for any fractional units) shall vest and become Vested RSUs on the first

anniversary of the Date of Grant (the “Initial Vesting Date”), provided the Participant is employed by (or,

if the Participant is a Contractor or an Outside Director, is providing services to) the Company or a Subsidiary on such date;

ii.

An additional one-thirty-sixth (1/36th) of the remaining Awarded Units (rounded down for any fractional units) shall vest and become

Vested RSUs on each of the first thirty-five (35) monthly anniversaries of the Initial Vesting Date, provided the Participant is employed

by (or, if the Participant is a Contractor or an Outside Director, is providing services to) the Company or a Subsidiary on the applicable

vesting date; and

iii.

The remaining Awarded Units shall vest and become Vested RSUs on the fourth anniversary of the Date of Grant, provided the Participant

is employed by (or, if the Participant is a Contractor or an Outside Director, is providing services to) the Company or a Subsidiary

on such date.

Notwithstanding

the foregoing, upon the occurrence of (i) a Change in Control, all then-outstanding Unvested RSUs shall immediately vest and become Vested

RSUs immediately prior to such Change in Control, and all then-outstanding Vested RSUs (including any such accelerated Vested RSUs) shall

be settled in accordance with Section 3(b), with the Settlement Date for such Vested RSUs being the date of such Change in Control

(or, to the extent required by Section 409A of the Code, such later date as is permitted under Section 3(b) and Section 24), and (ii)

a Termination of Service by the Company without Cause (defined below) or by the Participant for Good Reason (defined below), the Unvested

RSUs that were otherwise scheduled to vest on the monthly anniversary of the Initial Vesting Date next following the date of such Termination

of Service shall immediately vest and become Vested RSUs as of the date of such Termination of Service, and any remaining Unvested RSUs

that were otherwise scheduled to vest after such monthly anniversary date shall be forfeited in accordance with Section 4.

Subject to the provisions of the Plan and this Agreement, Vested RSUs shall not be settled in shares of Common Stock upon vesting. Instead,

subject to Section 24 and Section 25 of this Agreement, the Company shall settle the Vested RSUs by issuing to the Participant

a number of whole shares of Common Stock equal to the number of Vested RSUs then outstanding on the earliest to occur of (i) a Change

in Control and (ii) the Participant’s Termination of Service (the applicable date, the “Settlement Date”);

provided, however, that if the Participant’s Termination of Service is by the Company for Cause, any then-outstanding Vested RSUs

shall be forfeited and shall not be settled. For the avoidance of doubt, any Awarded Units that become Vested RSUs pursuant to Section

3(a), whether pursuant to continued service or accelerated vesting, shall remain outstanding as Vested RSUs following vesting unless

and until settled in accordance with this Section 3(b). Issuance of the shares of Common Stock shall be made as soon as administratively

practicable following the Settlement Date, and in no event later than sixty (60) days following the Settlement Date, subject in all events

to Section 409A of the Code.

For purposes of this Agreement, the terms “Cause” and “Good Reason” shall have the

definitions assigned to such terms in that certain Employment Agreement, dated ________________________, by and between the Company and

the Participant.

Forfeiture of Awarded Units. Except as otherwise provided in Section 3(a), upon the Participant’s Termination of

Service for any reason, the Participant shall be deemed to have forfeited all Unvested RSUs. In addition, upon the Participant’s

Termination of Service by the Company for Cause, all then-outstanding Vested RSUs shall be forfeited to the extent not previously settled

in accordance with Section 3(b). Upon forfeiture, all of the Participant’s rights with respect to the forfeited Unvested

RSUs or Vested RSUs, as applicable, shall cease and terminate, without any further obligation on the part of the Company.

Who May Receive Shares Issued Upon Settlement of Awarded Units. During the lifetime of the Participant, any shares of Common Stock

issued in settlement of Awarded Units may be received only by the Participant or his or her legal representative. If the Participant

dies prior to the settlement of his or her Awarded Units in accordance with Section 3 above, any shares of Common Stock issuable

in settlement of such Awarded Units may be received by the individual or individuals entitled to receive the property of the Participant

pursuant to the applicable laws of descent and distribution.

No Fractional Shares. Awarded Units shall be settled only in respect of whole shares of Common Stock, and no fractional share

of Common Stock shall be issued.

Nonassignability. The Awarded Units are not assignable or transferable by the Participant except by will or by the laws of descent

and distribution.

Rights as Stockholder. The Participant will have no rights as a stockholder with respect to any shares covered by this Agreement

until the issuance of a certificate or certificates to the Participant or the registration of such shares in the Participant’s

name for the shares of Common Stock. The Awarded Units shall be subject to the terms and conditions of this Agreement. Except as otherwise

provided in Section 9 hereof, no adjustment shall be made for dividends or other rights for which the record date is prior to

the issuance of such certificate or certificates or the registration of such shares in the Participant’s name. The Participant,

by his or her execution of this Agreement, agrees to execute any documents requested by the Company in connection with the issuance of

the shares of Common Stock.

Adjustment of Number of Awarded Units and Related Matters. The number of shares of Common Stock covered by the Awarded Units shall

be subject to adjustment in accordance with Articles 11-13 of the Plan.

10.

Specific Performance. The parties acknowledge that remedies at law will be inadequate remedies for breach of this Agreement and

consequently agree that this Agreement shall be enforceable by specific performance. The remedy of specific performance shall be cumulative

of all of the rights and remedies at law or in equity of the parties under this Agreement.

11.

Participant’s Representations. Notwithstanding any of the provisions hereof, the Participant hereby agrees that the Company

will not be obligated to issue any shares of Common Stock to the Participant hereunder, if the issuance of such shares shall constitute

a violation by the Participant or the Company of any provision of any law or regulation of any governmental authority. Any determination

in this connection by the Company shall be final, binding, and conclusive. The obligations of the Company and the rights of the Participant

are subject to all Applicable Laws.

12.

Investment Representation. Unless the shares of Common Stock are issued to the Participant in a transaction registered under applicable

federal and state securities laws, by his or her execution hereof, the Participant represents and warrants to the Company that all Common

Stock which may be acquired hereunder will be acquired by the Participant for investment purposes for his or her own account and not

with any intent for resale or distribution in violation of federal or state securities laws. Unless the Common Stock is issued to him

or her in a transaction registered under the applicable federal and state securities laws, all certificates issued with respect to the

Common Stock shall bear an appropriate restrictive investment legend and shall be held indefinitely, unless they are subsequently registered

under the applicable federal and state securities laws or the Participant obtains an opinion of counsel, in form and substance satisfactory

to the Company and its counsel, that such registration is not required.

13.

Participant’s Acknowledgments. The Participant acknowledges that a copy of the Plan has been made available for his or her

review by the Company and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts this Award

subject to all the terms and provisions thereof. The Participant hereby agrees to accept as binding, conclusive, and final all decisions

or interpretations of the Committee or the Board, as appropriate, upon any questions arising under the Plan or this Agreement.

14.

Law Governing. This Agreement shall be governed by, construed, and enforced in accordance with the laws of the State of Delaware

(excluding any conflict of laws rule or principle of Delaware law that might refer the governance, construction, or interpretation of

this Agreement to the laws of another state).

15.

No Right to Continue Service or Employment. Nothing herein shall be construed to confer upon the Participant the right to continue

in the employ or to provide services to the Company or any Subsidiary, whether as an Employee, Contractor, or Outside Director, or to

interfere with or restrict in any way the right of the Company or any Subsidiary to discharge the Participant as an Employee, Contractor,

or Outside Director at any time.

16.

Legal Construction. In the event that any one or more of the terms, provisions, or agreements that are contained in this Agreement

shall be held by a court of competent jurisdiction to be invalid, illegal, or unenforceable in any respect for any reason, the invalid,

illegal, or unenforceable term, provision, or agreement shall not affect any other term, provision, or agreement that is contained in

this Agreement, and this Agreement shall be construed in all respects as if the invalid, illegal, or unenforceable term, provision, or

agreement had never been contained herein.

17.

Covenants and Agreements as Independent Agreements. Each of the covenants and agreements that are set forth in this Agreement

shall be construed as a covenant and agreement independent of any other provision of this Agreement. The existence of any claim or cause

of action of the Participant against the Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to

the enforcement by the Company of the covenants and agreements that are set forth in this Agreement.

18.

Entire Agreement. This Agreement, together with the Plan, supersede any and all other prior understandings and agreements, either

oral or in writing, between the parties with respect to the subject matter hereof and constitute the sole and only agreements between

the parties with respect to the said subject matter. All prior negotiations and agreements between the parties with respect to the subject

matter hereof are merged into this Agreement. Each party to this Agreement acknowledges that no representations, inducements, promises,

or agreements, orally or otherwise, have been made by any party or by anyone acting on behalf of any party, which are not embodied in

this Agreement or the Plan and that any agreement, statement, or promise that is not contained in this Agreement or the Plan shall not

be valid or binding or of any force or effect.

19.

Parties Bound. The terms, provisions, and agreements that are contained in this Agreement shall apply to, be binding upon, and

inure to the benefit of the parties and their respective heirs, executors, administrators, legal representatives, and permitted successors

and assigns, subject to the limitation on assignment expressly set forth herein.

20.

Modification. No change or modification of this Agreement shall be valid or binding upon the parties unless the change or modification

is in writing and signed by the parties; provided, however, that the Company may change or modify this Agreement without

the Participant’s consent or signature if the Company determines, in its sole discretion, that such change or modification is necessary

for purposes of compliance with or exemption from the requirements of Section 409A of the Code or any regulations or other guidance issued

thereunder. Notwithstanding the preceding sentence, the Company may amend the Plan to the extent permitted by the Plan.

21.

Headings. The headings that are used in this Agreement are used for reference and convenience purposes only and do not constitute

substantive matters to be considered in construing the terms and provisions of this Agreement.

22.

Gender and Number. Words of any gender used in this Agreement shall be held and construed to include any other gender, and words

in the singular number shall be held to include the plural, and vice versa, unless the context requires otherwise.

23.

Notice. Any notice required or permitted to be delivered hereunder shall be deemed to be delivered only when actually received

by the Company or by the Participant, as the case may be, at the addresses set forth below, or at such other addresses as they have theretofore

specified by written notice delivered in accordance herewith:

Notice to the Company shall be addressed and delivered as follows:

Enveric

Biosciences, Inc.

245 First Street, Riverview II, 18th Floor

Cambridge, MA 02142

Attn: Kevin Coveney

Email: kcoveney@enveric.com

Notice to the Participant shall be addressed and delivered

as set forth on the signature page.

24.

Section 409A; Six Month Delay. Notwithstanding anything herein to the contrary, to the extent required for compliance with Section

409A of the Code, a Termination of Service shall not be deemed to have occurred unless such termination also constitutes a “separation

from service” within the meaning of Section 409A of the Code. Further, notwithstanding anything herein to the contrary, if any

settlement of Awarded Units and issuance of shares of Common Stock is to occur on account of the Participant’s Termination of Service

(other than death), and if the Participant is a “specified employee” as defined in § 1.409A-1(i) of the final regulations

under Section 409A of the Code, then solely to the extent required under Section 409A of the Code, the issuance of such shares to the

Participant (determined after application of the withholding requirements set forth in Section 25 below) shall not occur until

the date that is six (6) months following the date of the Participant’s Termination of Service (or, if earlier, the date of death

of the Participant).

25.

Tax Requirements. The Participant is hereby advised to consult immediately with his or her own tax advisor regarding the tax consequences

of this Agreement. Unless the Company otherwise consents in writing to an alternative withholding method, the Company, or if applicable,

any Subsidiary (for purposes of this Section 25, the term “Company” shall be deemed to include any applicable

Subsidiary) shall have the right to deduct from all amounts paid in cash or other form in connection with the Plan, any federal, state,

local, or other taxes required by law to be withheld in connection with this Award. The Company may, in its sole discretion and prior

to the Settlement Date, require the Participant receiving shares of Common Stock upon settlement of Awarded Units to pay the Company

the amount of any taxes that the Company is required to withhold in connection with the Participant’s income arising with respect

to this Award. Such payments shall be required to be made prior to the delivery of any certificate or the registration of such shares

in the Participant’s name for such shares of Common Stock. Such payment may be made by (i) the delivery of cash to the Company

in an amount that equals or exceeds (to avoid the issuance of fractional shares) the required tax withholding obligations of the Company;

(ii) if the Company, in its sole discretion, so consents in writing, the actual delivery by the Participant to the Company of shares

of Common Stock that the Participant has not acquired from the Company within six (6) months prior to the Settlement Date, which shares

so delivered have an aggregate Fair Market Value that equals or exceeds (to avoid the issuance of fractional shares) the required tax

withholding payment; or (iii) any combination of (i) or (ii). Notwithstanding the foregoing, the Company may, in its sole discretion,

withhold any such taxes from any other cash remuneration otherwise paid by the Company to the Participant or withhold the number of shares

otherwise issuable upon settlement of the Awarded Units with an aggregate Fair Market Value that equals or exceeds (to avoid the issuance

of fractional shares) the required tax withholding obligations of the Company; provided, however, if the Participant is a “specified

employee” as defined in § 1.409A-1(i) of the final regulations under Section 409A of the Code who is subject to the six (6)

months delay provided for in Section 24 above, the Company shall withhold the number of shares attributable to the employment

taxes on the date of the Participant’s Termination of Service and withhold the number of shares attributable to the income taxes

on the date which occurs six (6) months following the date of the Participant’s Termination of Service (or, if earlier, the date

of death of the Participant).

[Remainder

of Page Intentionally Left Blank;

Signature Page Follows.]

WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer, and the Participant, to evidence

his or her consent and approval of all the terms hereof, has duly executed this Agreement, as of the date specified in Section 1

hereof.

COMPANY:

Enveric

Biosciences, Inc.

By:

Name:

Title:

PARTICIPANT:

Signature

Name:

Address:

c/o

Enveric Biosciences, Inc.

245

First Street, Riverview II, 18th Floor

Cambridge,

MA 02142

EX-10.2

Filename: ex10-2.htm · Sequence: 3

Exhibit

10.2

RESTRICTED

STOCK AWARD AGREEMENT

ENVERIC

BIOSCIENCES, INC.

2020

LONG-TERM INCENTIVE PLAN

1. Grant

of Award. Pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the “Plan”) for Employees,

Contractors, and Outside Directors of Enveric Biosciences, Inc., a Delaware corporation (the “Company”), the

Company grants to

(the

“Participant”)

Award of Restricted Stock in accordance with Section 6.4 of the Plan. The number of shares of Common Stock awarded under this Restricted

Stock Award Agreement (the “Agreement”) is ______________ (_______) shares (the “Awarded Shares”).

The “Date of Grant” of this Award is ___________________.

2. Subject

to Plan. This Agreement is subject to the terms and conditions of the Plan, and the terms of the Plan shall control to the extent

not otherwise inconsistent with the provisions of this Agreement. The capitalized terms used herein that are defined in the Plan shall

have the same meanings assigned to them in the Plan. This Agreement is subject to any rules promulgated pursuant to the Plan by the Board

or the Committee and communicated to the Participant in writing.

3. Vesting.

Subject to certain restrictions and conditions set forth in the Plan and in the terms of this Agreement, the Awarded Shares shall fully

vest on ____________________ (the “Vesting Date”), provided the Participant is employed by (or, if the Participant

is a Contractor or an Outside Director, is providing services to) the Company or a Subsidiary on that date.

4. Forfeiture

of Awarded Shares. Awarded Shares that are not vested in accordance with Section 3 shall be forfeited on the date of the Participant’s

Termination of Service prior to the Vesting Date for any reason. Upon forfeiture, all of the Participant’s rights with respect

to the forfeited Awarded Shares shall cease and terminate, without any further obligations on the part of the Company.

5. Restrictions

on Awarded Shares. Subject to the provisions of the Plan and the terms of this Agreement, from the Date of Grant until the Vesting

Date (the “Restriction Period”), the Participant shall not be permitted to sell, transfer, pledge, hypothecate,

margin, assign, or otherwise encumber any of the Awarded Shares. Except for these limitations, the Committee may, in its sole discretion,

remove any or all of the restrictions on such Awarded Shares whenever it may determine that, by reason of changes in Applicable Laws

or changes in circumstances after the date of this Agreement, such action is appropriate.

6. Legend.

The following legend shall be placed on all certificates issued representing Awarded Shares:

the face of the certificate:

“Transfer

of this stock is restricted in accordance with conditions printed on the reverse of this certificate.”

the reverse:

“The

shares of stock evidenced by this certificate are subject to and transferable only in accordance with that certain Enveric Biosciences,

Inc. 2020 Long-Term Incentive Plan, a copy of which is on file at the principal office of the Company in Naples, Florida. No transfer

or pledge of the shares evidenced hereby may be made except in accordance with and subject to the provisions of said Plan. By acceptance

of this certificate, any holder, transferee or pledgee hereof agrees to be bound by all of the provisions of said Plan.”

The

following legend shall be inserted on a certificate evidencing Common Stock issued under the Plan if the shares were not issued in a

transaction registered under the applicable federal and state securities laws:

“Shares

of stock represented by this certificate have been acquired by the holder for investment and not for resale, transfer or distribution,

have been issued pursuant to exemptions from the registration requirements of applicable state and federal securities laws, and may not

be offered for sale, sold or transferred other than pursuant to effective registration under such laws, or in transactions otherwise

in compliance with such laws, and upon evidence satisfactory to the Company of compliance with such laws, as to which the Company may

rely upon an opinion of counsel satisfactory to the Company.”

All

Awarded Shares owned by the Participant shall be subject to the terms of this Agreement and shall be represented by a certificate or

certificates bearing the foregoing legend.

7. Delivery

of Certificates; Registration of Shares. The Company shall deliver certificates for the Awarded Shares to the Participant or shall

register the Awarded Shares in the Participant’s name, free of restriction under this Agreement, promptly after, and only after,

the Restriction Period has expired without forfeiture pursuant to Section 4. In connection with any issuance of a certificate

for Restricted Stock, the Participant shall endorse such certificate in blank or execute a stock power in a form satisfactory to the

Company in blank and deliver such certificate and executed stock power to the Company.

8. Rights

of a Stockholder. Except as provided in Section 4 and Section 5 above, the Participant shall have, with respect to

his or her Awarded Shares, all of the rights of a stockholder of the Company, including the right to vote the shares and the right to

receive any dividends thereon.

9. Voting.

The Participant, as record holder of the Awarded Shares, has the exclusive right to vote, or consent with respect to, such Awarded Shares

until such time as the Awarded Shares are transferred in accordance with this Agreement; provided, however, that this Section

9 shall not create any voting right where the holders of such Awarded Shares otherwise have no such right.

10. Adjustment

to Number of Awarded Shares. The number of Awarded Shares shall be subject to adjustment in accordance with Articles 11-13

of the Plan.

11. Specific

Performance. The parties acknowledge that remedies at law will be inadequate remedies for a breach of this Agreement and consequently

agree that this Agreement shall be enforceable by specific performance. The remedy of specific performance shall be cumulative of all

of the rights and remedies at law or in equity of the parties under this Agreement.

12. Participant’s

Representations. Notwithstanding any of the provisions hereof, the Participant hereby agrees that he or she will not acquire any

Awarded Shares, and that the Company will not be obligated to issue any Awarded Shares to the Participant hereunder, if the issuance

of such shares shall constitute a violation by the Participant or the Company of any provision of any law or regulation of any governmental

authority. Any determination in this connection by the Company shall be final, binding, and conclusive. The rights and obligations of

the Company and the rights and obligations of the Participant are subject to all Applicable Laws, rules, and regulations.

13. Investment

Representation. Unless the Awarded Shares are issued in a transaction registered under applicable federal and state securities laws,

by his or her execution hereof, the Participant represents and warrants to the Company that all Common Stock which may be purchased and/or

received hereunder will be acquired by the Participant for investment purposes for his or her own account and not with any intent for

resale or distribution in violation of federal or state securities laws. Unless the Common Stock is issued to him or her in a transaction

registered under the applicable federal and state securities laws, all certificates issued with respect to the Common Stock shall bear

an appropriate restrictive investment legend and shall be held indefinitely, unless they are subsequently registered under the applicable

federal and state securities laws or the Participant obtains an opinion of counsel, in form and substance satisfactory to the Company

and its counsel, that such registration is not required.

14. Participant’s

Acknowledgments. The Participant acknowledges that a copy of the Plan has been made available for his or her review by the Company

and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts this Award subject to all the terms

and provisions thereof. The Participant hereby agrees to accept as binding, conclusive, and final all decisions or interpretations of

the Committee or the Board, as applicable, upon any questions arising under the Plan or this Agreement.

15. Law

Governing. This Agreement shall be governed by, construed, and enforced in accordance with the laws of the State of Delaware (excluding

any conflict of laws rule or principle of Delaware law that might refer the governance, construction, or interpretation of this Agreement

to the laws of another state).

16. No

Right to Continue Service or Employment. Nothing herein shall be construed to confer upon the Participant the right to continue in

the employ or to provide services to the Company or any Subsidiary, whether as an Employee, Contractor, or Outside Director, or to interfere

with or restrict in any way the right of the Company or any Subsidiary to discharge the Participant as an Employee, Contractor, or Outside

Director at any time.

17. Legal

Construction. In the event that any one or more of the terms, provisions, or agreements that are contained in this Agreement shall

be held by a court of competent jurisdiction to be invalid, illegal, or unenforceable in any respect for any reason, the invalid, illegal,

or unenforceable term, provision, or agreement shall not affect any other term, provision, or agreement that is contained in this Agreement,

and this Agreement shall be construed in all respects as if the invalid, illegal, or unenforceable term, provision, or agreement had

never been contained herein.

18. Covenants

and Agreements as Independent Agreements. Each of the covenants and agreements that are set forth in this Agreement shall be construed

as a covenant and agreement independent of any other provision of this Agreement. The existence of any claim or cause of action of the

Participant against the Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement

by the Company of the covenants and agreements that are set forth in this Agreement.

19. Entire

Agreement. This Agreement together with the Plan supersede any and all other prior understandings and agreements, either oral or

in writing, between the parties with respect to the subject matter hereof and constitute the sole and only agreements between the parties

with respect to the said subject matter. All prior negotiations and agreements between the parties with respect to the subject matter

hereof are merged into this Agreement. Each party to this Agreement acknowledges that no representations, inducements, promises, or agreements,

orally or otherwise, have been made by any party or by anyone acting on behalf of any party, which are not embodied in this Agreement

or the Plan and that any agreement, statement, or promise that is not contained in this Agreement or the Plan shall not be valid or binding

or of any force or effect.

20. Parties

Bound. The terms, provisions, and agreements that are contained in this Agreement shall apply to, be binding upon, and inure to the

benefit of the parties and their respective heirs, executors, administrators, legal representatives, and permitted successors and assigns,

subject to the limitation on assignment expressly set forth herein. No person shall be permitted to acquire any Awarded Shares without

first executing and delivering an agreement in the form satisfactory to the Company making such person or entity subject to the restrictions

on transfer contained herein.

21. Modification.

No change or modification of this Agreement shall be valid or binding upon the parties unless the change or modification is in writing

and signed by the parties hereto. Notwithstanding the preceding sentence, the Company may amend the Plan to the extent permitted by the

Plan.

22. Headings.

The headings that are used in this Agreement are used for reference and convenience purposes only and do not constitute substantive matters

to be considered in construing the terms and provisions of this Agreement.

23. Gender

and Number. Words of any gender used in this Agreement shall be held and construed to include any other gender, and words in the

singular number shall be held to include the plural, and vice versa, unless the context requires otherwise.

24. Notice.

Any notice required or permitted to be delivered hereunder shall be deemed to be delivered only when actually received by the Company

or by the Participant, as the case may be, at the addresses set forth below, or at such other addresses as they have theretofore specified

by written notice delivered in accordance herewith:

a. Notice

to the Company shall be addressed and delivered as follows:

Enveric

Biosciences, Inc.

245

First Street, Riverview II, 18th Floor

Cambridge,

MA 02142

Attn:

Kevin Coveney

Email:

kcoveney@enveric.com

b. Notice

to the Participant shall be addressed and delivered as set forth on the signature page.

25. Tax

Requirements. The Participant is hereby advised to consult immediately with his or her own tax advisor regarding the tax consequences

of this Agreement, the method and timing for filing an election to include this Agreement in income under Section 83(b) of the Code,

and the tax consequences of such election. By execution of this Agreement, the Participant agrees that if the Participant makes such

an election, the Participant shall provide the Company with written notice of such election in accordance with the regulations promulgated

under Section 83(b) of the Code. The Company or, if applicable, any Subsidiary (for purposes of this Section 25, the term

“Company” shall be deemed to include any applicable Subsidiary), shall have the right to deduct from all amounts

paid in cash or other form in connection with the Plan, any federal, state, local, or other taxes required by law to be withheld in connection

with this Award. The Company may, in its sole discretion, also require the Participant receiving shares of Common Stock issued under

the Plan to pay the Company the amount of any taxes that the Company is required to withhold in connection with the Participant’s

income arising with respect to this Award. Such payments shall be required to be made when requested by the Company and may be required

to be made prior to the delivery of any certificate representing shares of Common Stock or the registration of such shares in the Participant’s

name. Such payment may be made by (a) the delivery of cash to the Company in an amount that equals or exceeds (to avoid the issuance

of fractional shares) the required tax withholding obligations of the Company; (b) if the Company, in its sole discretion, so consents

in writing, the actual delivery by the Participant to the Company of shares of Common Stock, other than Common Stock that the Participant

has acquired from the Company within six (6) months prior thereto, which shares so delivered have an aggregate Fair Market Value that

equals or exceeds (to avoid the issuance of fractional shares) the required tax withholding payment; or (c) any combination of (a) and

(b). The Company may, in its sole discretion, withhold any such taxes from any other cash remuneration otherwise paid by the Company

to the Participant.

[Remainder

of Page Intentionally Left Blank; Signature Page Follows.]

WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer, and the Participant, to evidence

his or her consent and approval of all the terms hereof, has duly executed this Agreement, as of the date specified in Section 1

hereof.

COMPANY:

Enveric

Biosciences, Inc.

By:

Name:

Kevin

Coveney

Title:

Chief

Financial Officer

PARTICIPANT:

Signature

Name:

Address:

c/o

Enveric Biosciences, Inc.

245

First Street, Riverview II, 18th Floor

Cambridge,

MA 02142

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

May 22, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 22, 2026

Entity File Number

001-38286

Entity Registrant Name

Enveric

Biosciences, Inc.

Entity Central Index Key

0000890821

Entity Tax Identification Number

95-4484725

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Enveric

Biosciences, Inc.

Entity Address, Address Line Two

245

First Street, Riverview II

Entity Address, Address Line Three

18th Floor

Entity Address, City or Town

Cambridge

Entity Address, State or Province

Entity Address, Postal Zip Code

02142

City Area Code

(617)

Local Phone Number

444-8400

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

stock, par value $0.01 per share

Trading Symbol

ENVB

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration